BLACKHOUSE-MEDIA
11.5.2022 09:01:09 CEST | Business Wire | Press release
In its continuing effort to bring the UEFA Champions League (UCL) experience closer to more football fans around the world, Heineken has staged its most elaborate Trophy Tour in Africa yet. The 10-day tour, which ended on April 13 in Abuja, Nigeria, ahead of the 2022 final match on May 28, included several public events that featured the UCL trophy at major stops in the Democratic Republic of Congo, Mozambique, Ethiopia, and Nigeria. Fans from Rwanda and Congo Brazzaville also attended the tour in Nigeria and DRC respectively.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509006222/en/
The events around the tour included open-truck city parades, novelty matches with local celebrities, UCL quarter final match viewings, fan meet and greets, photo sessions, media rounds, Afrobeats concerts, and visits to government ministries in charge of football.
Heineken, sold in 192 countries around the world, has been a sponsor of the UEFA Champions League since 2005 and the company’s leadership said its Africa-wide trophy tour for the 2021/2022 season was structured to reach 50,000 Africans directly while an estimated 10 million more are reached via media coverage.
A highlight of the trophy tour was a Heineken-sponsored football match in Lagos, Nigeria. It pitted Nigerian music superstars and football legends against senior staff of Nigerian Breweries, which is the local Heineken brewer, and the Trophy Tour Ambassador, professional coach and former Dutch international midfielder, Clarence Seedorf.
BET Awards-winning Afrobeats star Davido captained Team Nigeria, which had ex-Nigerian internationals Austin Jay Jay Okocha, Daniel Amokachi, and Taribo West. Also on the squad were rapper M.I. Abaga, R&B singer Darey, and Nigerian Breweries Marketing Director, Emmanuel Oriakhi. Seedorf led Team Heineken, playing, among others, Nigerian Breweries Finance Director, Rob Kleinjan; and the company’s Supply Chain Director, Martin Kochl.
The novelty match preceded an Afrobeats concert that was headlined by African superstar, Davido and Peruzzi, another topflight Nigerian singer. Members of the Heineken management team and Seedorf then met with the Nigerian Minister of Youth and Sports Development, Sunday Dare, at the MKO Abiola stadium in Abuja, the country’s capital.
The Union of European Football Associations, the umbrella organisation for 55 national football associations across Europe, organizes the Champions League as an annual competition among top-division football clubs. The 2022 final match is slated for May 28 at the Stade de France in Paris.
“The goal of the Trophy Tour is to inspire a new generation of African footballers and appreciate fans for their love of the UEFA Champions League and Heineken,” said Heineken’s Senior Global Director, Bram Westerbrink.
The continent’s importance to the growth of football and the UCL is evident, Bram also noted. Several European clubs in the English, French, Italian, Spanish, and German leagues have notable African following, with many of the fans organising meetups and celebrations when their favourite teams record tournament successes. With more than 100 Africans currently playing professionally, over 25 Champions League winners from Africa, and about 300 million African fans, football has taken hold as the most popular sport on the continent.
“This is why Heineken is proud to celebrate its association with the UEFA Champions League,” said Hans Erik Tuijt, Director, Global Heineken Sponsorships, adding that Heineken has the highest awareness on the continent as a sponsor of the UEFA Champions League.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509006222/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom